<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040673</url>
  </required_header>
  <id_info>
    <org_study_id>18/044/GHT</org_study_id>
    <secondary_id>245612</secondary_id>
    <secondary_id>18/LO/1545</secondary_id>
    <nct_id>NCT04040673</nct_id>
  </id_info>
  <brief_title>RAman For Thyroid cancER</brief_title>
  <acronym>RAFTER</acronym>
  <official_title>Evaluation of the Role of Vibrational Spectroscopy in the Diagnosis of Premalignant and Malignant Disease of the Thyroid RAFTER (RAman For Thyroid cancER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gloucestershire Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gloucestershire Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ex vivo vibrational spectroscopy (VS), including Raman spectroscopy (RS) of thyroid tissue
      samples, collected from patients undergoing routine diagnostic thyroid biopsies for diagnosis
      of potential thyroid cancer. Raman spectra are to be correlated with consensus histopathology
      and clinical outcomes. Multivariate analysis to be used to evaluate the classification
      accuracy of VS ex vivo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Investigators (The Biophotonics Research Unit, University of Exeter and University of
      Bristol) have developed these &quot;smart needle&quot; probes, consisting of fibre-optics within a fine
      needle for investigating cancer below the skin's surface. It is difficult to create a
      sensitive probe to fit inside a needle; however, The Investigators have demonstrated this
      approach in lymph node tissue samples from 68 patients in the laboratory, where The
      Investigators showed that our probe could detect cancer with a high level of accuracy.

      Following on from our success with lymph nodes The Investigators wish to trial our smart
      needle on excised thyroid to demonstrate the device in another ENT cancer. Earlier studies
      have shown that thyroid cancer can be diagnosed using RS under a microscope with an accuracy
      greater than 78%.9 By eliminating the need for unnecessary surgery by diagnosis with our
      device, The Investigators will minimise the risk to patients, eliminate delays in obtaining
      results and reduce the cost of surgery and overnight stay in the hospital. The Investigators
      wish to advance this device closer to the clinic for a new cancer to improve the patient care
      pathway and remove the need for unnecessary surgery, by facilitating the work of the one-stop
      ENT diagnostic outpatient clinics.

      The study consists of measuring spectra of new tissue taken during routine diagnostic
      surgical thyroid lobectomy.

      New tissue for this project will be collected during routine biopsy will be rapidly analysed
      by a spectrometer before proceeding with conventional histopathological analysis. The new
      tissue will consist of thyroid and adjacent tissue biopsies. No additional tissue will be
      taken for this research, The Investigators only plan to measure samples taken during routine
      diagnosis in under 5 minutes, before passing the sections back to the surgical team for
      routine histopathological analysis.

      Anonymous background information relevant to known risk factors, family history and details
      of any treatment, menopausal status, details relevant medical procedures, and any treatment
      for thyroid cancer will be provided with the samples. An example of the report can be found
      in Appendix 3. Tissue specimens taken during routine clinical care are to be subjected to ex
      vivo vibrational spectroscopic analysis immediately prior to being sent for routine
      histopathological analysis. Vibrational spectra are to be correlated with consensus
      histopathology of adjacent sections. Multivariate analysis is to be used to evaluate the
      classification accuracy of VS ex vivo. The vibrational spectra will be assessed for both
      prognostic as well as diagnostic information.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test the Raman needle probe on freshly exised tissue</measure>
    <time_frame>1 year</time_frame>
    <description>Measure Raman spectra and match with histopathology. Perform leave-one-out analysis to measure performance of diagnosis of Raman spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculate diagnostic performance of Raman spectroscopy probe for thyroid cancer</measure>
    <time_frame>1 year</time_frame>
    <description>Diagnostic performance (specificity and sensitivity) of Raman spectroscopy (RS) for differentiation of thyroid cancer vs normal benign (no cancer).
Diagnostic performance of RS for differentiation of thyroid cancer types.
Papillary thyroid cancer
Follicular thyroid cancer
Anaplastic thyroid cancer
Medullary thyroid cancer</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thyroid Diseases</condition>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Normal benign</arm_group_label>
    <description>participants with normal benign nodules (no cancer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follicular thyroid cancer</arm_group_label>
    <description>participants with follicular thyroid cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Papillary thyroid cancer</arm_group_label>
    <description>participants with papillary thyroid cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anaplastic thyroid cancer</arm_group_label>
    <description>participants with anaplastic thyroid cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medullary thyroid cancer</arm_group_label>
    <description>participants with medullary thyroid cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thyroid lobectomy</intervention_name>
    <description>routine surgical removal of thyroid for biopsy</description>
    <arm_group_label>Anaplastic thyroid cancer</arm_group_label>
    <arm_group_label>Follicular thyroid cancer</arm_group_label>
    <arm_group_label>Medullary thyroid cancer</arm_group_label>
    <arm_group_label>Normal benign</arm_group_label>
    <arm_group_label>Papillary thyroid cancer</arm_group_label>
    <other_name>thyroid nodule removal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Raman spectroscopy probe measurement</intervention_name>
    <description>The measurement of Raman spectra from the excised tissue</description>
    <arm_group_label>Anaplastic thyroid cancer</arm_group_label>
    <arm_group_label>Follicular thyroid cancer</arm_group_label>
    <arm_group_label>Medullary thyroid cancer</arm_group_label>
    <arm_group_label>Normal benign</arm_group_label>
    <arm_group_label>Papillary thyroid cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending for routine diagnostic biopsy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing routine diagnostic thyroid biopsy at surgery

        Exclusion Criteria:

          -  Patients are unable to provide informed consent.

          -  Patients not attending for standard diagnostic biopsy for thyroid cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julia Hall</last_name>
    <phone>+443004225466</phone>
    <email>julia.hall9@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biophotonics Research Unit</name>
      <address>
        <city>Gloucester</city>
        <state>Gloucestershire</state>
        <zip>GL1 2AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Julia Hall</last_name>
      <email>julia.hall9@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Alexander P Dudgeon, PhD</last_name>
      <phone>+443004225476</phone>
      <email>alex.dudgeon@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander P Dudgeon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine A Kendall, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlie Hall, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maryam Nowghani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, Benson CB, Doubilet PM, Cibas ES, Barletta J, Cho N, Gawande A, Ruan D, Moore FD Jr, Pou K, Larsen PR, Alexander EK. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab. 2013 Feb;98(2):564-70. doi: 10.1210/jc.2012-2968. Epub 2012 Dec 28.</citation>
    <PMID>23275525</PMID>
  </reference>
  <reference>
    <citation>Jenkins CA, Lewis PD, Dunstan PR, Harris DA. Role of Raman spectroscopy and surface enhanced Raman spectroscopy in colorectal cancer. World J Gastrointest Oncol. 2016 May 15;8(5):427-38. doi: 10.4251/wjgo.v8.i5.427. Review.</citation>
    <PMID>27190582</PMID>
  </reference>
  <reference>
    <citation>Feng X, Moy AJ, Nguyen HTM, Zhang J, Fox MC, Sebastian KR, Reichenberg JS, Markey MK, Tunnell JW. Raman active components of skin cancer. Biomed Opt Express. 2017 May 4;8(6):2835-2850. doi: 10.1364/BOE.8.002835. eCollection 2017 Jun 1.</citation>
    <PMID>28663910</PMID>
  </reference>
  <reference>
    <citation>Crow P, Barrass B, Kendall C, Hart-Prieto M, Wright M, Persad R, Stone N. The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines. Br J Cancer. 2005 Jun 20;92(12):2166-70.</citation>
    <PMID>15928665</PMID>
  </reference>
  <reference>
    <citation>Rau JV, Fosca M, Graziani V, Taffon C, Rocchia M, Caricato M, Pozzilli P, Onetti Muda A, Crescenzi A. Proof-of-concept Raman spectroscopy study aimed to differentiate thyroid follicular patterned lesions. Sci Rep. 2017 Nov 2;7(1):14970. doi: 10.1038/s41598-017-14872-1.</citation>
    <PMID>29097686</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gloucestershire Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Alex Dudgeon</investigator_full_name>
    <investigator_title>Post-Doctoral Research Fellow</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>Raman</keyword>
  <keyword>thyroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pathology reports will be linked using a pseudo-anonymous unique study identifier</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT04040673/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

